International Flavors & Fragrances (IFF) stock moved after Q1 2026 results topped analyst revenue and adjusted earnings estimates, as management reaffirmed full year guidance despite lower year on year sales and ongoing portfolio reshaping.

The Q1 beat and reaffirmed guidance come after a strong year to date, with a 15.04% year to date share price return and a 1 year total shareholder return of 8.21%. However, longer term total shareholder returns over 3 and 5 years have been subdued, suggesting recent momentum is still rebuilding from a weaker multi year backdrop.

If this kind of earnings driven move has your attention, it could be a moment to see what else is setting up in AI infrastructure and data center suppliers via the 40 AI infrastructure stocks.

With IFF trading at $78.26, sitting below the US$90.87 average analyst target and with an indicated intrinsic value discount of about 48%, investors may question whether there is still mispricing or whether the market is already incorporating expectations for future growth.

Most Popular Narrative: 13.7% Undervalued

IFF's most followed narrative pegs fair value at $90.71 versus the $78.26 last close, framing the Q1 reaction within a longer term rerating story.

Recent divestitures of commodity businesses (e.g., Pharma Solutions, Soy Crush, Concentrates, Lecithin) and the ongoing strategic evaluation of the Food Ingredients segment are increasing IFF's focus on differentiated, higher-margin, innovation-driven products, supporting future margin expansion and higher earnings quality. Ongoing investments in R&D and capacity (especially in Health & Biosciences, Taste, and Specialty Fragrance Ingredients) are strengthening the company's innovation pipeline; management expects these initiatives to accelerate revenue and profit growth beginning in 2026 and reaching full impact by 2027.

Curious what sits behind that $90.71 fair value, and why it uses a discount rate just under 8% with modest growth and margin rebuild included.

This widely followed narrative applies a 7.94% discount rate to IFF's projected cash flows, incorporates measured revenue growth and margin expansion, and arrives at a fair value of $90.71 per share. Compared with the current $78.26 share price, that suggests the narrative still sees a gap that depends on execution in areas such as portfolio reshaping, Health & Biosciences, and emerging market demand translating into earnings and cash generation.

Result: Fair Value of $90.71 (UNDERVALUED)

However, investors still need to weigh softer demand in key regions and ongoing pressure in Fragrance Ingredients, which could limit the margin rebuild that the fair value assumes.

Another Way To Look At Valuation

The narrative-based fair value of $90.71 points to upside, but IFF's 24.2x P/E is above its fair ratio of 21.3x, even though it trades below the US Chemicals average of 28.1x and a 42.5x peer average. Is the discount a cushion, or a warning that expectations are already rich?

Next Steps

Balancing those risks and rewards can feel tricky, so it helps to look at the numbers and sentiment yourself and decide quickly where you stand by reviewing the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities the screener highlights, so take a few minutes to see what else fits your checklist.

• Target potential value opportunities early by scanning screener containing 23 high quality undiscovered gems that may not yet be on most investors' radar.
• Strengthen your core holdings by filtering for companies in the solid balance sheet and fundamentals stocks screener (44 results) that focus on financial resilience and fundamentals.
• Reduce surprise risks by reviewing the 72 resilient stocks with low risk scores and focusing on stocks with more consistent risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.